You have 9 free searches left this month | for more free features.

retifanlimab

Showing 1 - 25 of 25

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Retifanlimab
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 4, 2023

Glioblastoma Multiforme Trial in Baltimore (Retifanlimab, Temozolomide, Radiation Therapy)

Recruiting
  • Glioblastoma Multiforme
  • Retifanlimab
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins Medical Institution
Dec 5, 2022

Pancreatic Adenocarcinoma Trial in Fairway (9-ING-41, Retifanlimab, Gemcitabine)

Active, not recruiting
  • Pancreatic Adenocarcinoma
  • Fairway, Kansas
    Kansas University Cancer center
Nov 2, 2022

Glioma, Glioblastoma Trial in United States (drug, radiation, procedure)

Recruiting
  • Glioma
  • Glioblastoma
  • Phoenix, Arizona
  • +3 more
Oct 13, 2022

Breast Cancer Female, Breast Tumor Female Trial in United States (SV-BR-1-GM, INCMGA00012, Low dose cyclophosphamide)

Recruiting
  • Breast Cancer
  • +3 more
  • SV-BR-1-GM
  • +3 more
  • Newport Beach, California
  • +9 more
Dec 8, 2022

Breast Cancer, Metastatic Breast Cancer, Breast Tumor Trial in Port Jefferson Station (SV-BR-1-GM, Cyclophosphamide, Interferon

Not yet recruiting
  • Breast Cancer
  • +4 more
  • SV-BR-1-GM
  • +4 more
  • Port Jefferson Station, New York
    New York Cancers & Blood Specialists
Oct 2, 2023

Merkel Cell Carcinoma Trial in Milan (Retifanlimab, Cisplatin, Etoposide)

Recruiting
  • Merkel Cell Carcinoma
  • Retifanlimab
  • +2 more
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Jan 4, 2023

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

DLBCL, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

Not yet recruiting
  • Glioma
  • +3 more
  • Retifanlimab
  • All-trans retinoic acid
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jul 22, 2022

Pancreatic Ductal Adenocarcinoma Trial in Miami (Trametinib, Ruxolitinib, Retifanlimab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Miami, Florida
    University of Miami
Jun 27, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Chuo Ku, Kashiwa (Retifanlimab, INCB001158, Retifanlimab + INCB001158)

Completed
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Retifanlimab
  • +2 more
  • Chuo Ku, Japan
  • +1 more
Feb 24, 2022

Advanced Neuroendocrine Tumor, Carcinoid Syndrome Trial (Retifanlimab, Telotristat Ethyl)

Withdrawn
  • Advanced Neuroendocrine Neoplasm
  • Carcinoid Syndrome
  • Retifanlimab
  • Telotristat Ethyl
  • (no location specified)
Sep 23, 2021

Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic Trial in Baltimore (Neoantigen Vaccine with Poly-ICLC adjuvant,

Not yet recruiting
  • Pancreatic Cancer Metastatic
  • Colorectal Cancer Metastatic
  • Neoantigen Vaccine with Poly-ICLC adjuvant
  • Retifanlimab
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Aug 5, 2022

Gastric Adenocarcinoma, Esophageal Adenocarcinoma Trial in Netherlands (Capecitabine, Oxaliplatin, Retifanlimab)

Recruiting
  • Gastric Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Amsterdam, Netherlands
  • +7 more
Jan 31, 2022

Advanced Malignancies Trial in Worldwide (Pemigatinib, Retifanlimab, Pembrolizumab)

Recruiting
  • Advanced Malignancies
  • Santa Monica, California
  • +6 more
Apr 6, 2022

Urothelial Carcinoma Trial in France, Italy, United States (retifanlimab, epacadostat, INCAGN02385)

Recruiting
  • Urothelial Carcinoma
  • retifanlimab
  • +3 more
  • Iowa City, Iowa
  • +11 more
Dec 1, 2022

Head Neck Cancer Trial (Retifanlimab, INCAGN02385, INCAGN02390)

Recruiting
  • Head and Neck Cancer
  • Retifanlimab
  • +3 more
  • Scottsdale, Arizona
  • +87 more
Dec 12, 2022

Endometrial Cancer Trial in Worldwide (retifanlimab, epacadostat, pemigatinib)

Recruiting
  • Endometrial Cancer
  • retifanlimab
  • +4 more
  • Anchorage, Alaska
  • +78 more
Jul 25, 2022

Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies Trial in

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • Los Angeles, California
  • +31 more
Jul 20, 2022

Squamous Cell Carcinoma of the Anal Canal Trial in Worldwide (carboplatin, paclitaxel, retifanlimab)

Recruiting
  • Squamous Cell Carcinoma of the Anal Canal
  • Tucson, Arizona
  • +85 more
Jun 13, 2022

NSCLC Trial (Retifanlimab, Placebo, Pemetrexed)

Withdrawn
  • Non-small Cell Lung Cancer
  • Retifanlimab
  • +7 more
  • (no location specified)
Jun 5, 2020

Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV NSCLC, Advanced/Metastatic

Withdrawn
  • Advanced and/or Metastatic Solid Tumors
  • +2 more
  • Retifanlimab
  • +5 more
  • (no location specified)
Apr 21, 2020

Squamous Cell Carcinoma of Anal Canal Trial in Worldwide (Retifanlimab)

Completed
  • Squamous Cell Carcinoma of Anal Canal
  • Retifanlimab
  • Duarte, California
  • +46 more
Jan 11, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Worldwide (retifanlimab)

Active, not recruiting
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • retifanlimab
  • Scottsdale, Arizona
  • +79 more
Nov 9, 2022